We don’t follow footsteps.
We create the path.

News & events

Best Places to Work 2017
Spark Therapeutics was named one of the “Best Places to Work” by the Philadelphia Business Journal

Read More read more

Q2 2017 earnings
Spark Therapeutics reports Q2 2017 financial results and recent business highlights

Read More read more

MAA submitted to the European Medicines Agency
Spark Therapeutics submitted a Marketing Authorization Application for its investigational gene therapy to the European Medicines Agency 

Read More read more

BLA filing acceptance
Spark Therapeutics announces FDA acceptance of BLA for filing with Priority Review of investigational gene therapy LUXTURNA™ (voretigene neparvovec)

Read More read more

We don’t follow footsteps. We create the path.

Our mission at Spark Therapeutics is to challenge the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable—until now. We have built a fully integrated company, combining our proprietary adeno-associated viral (AAV) gene therapy platform with excellence in R&D, manufacturing and commercial operations. Find out more about how we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases.

Learn More